How can pharmaceutical corporations successfully collaborate with tech startups?

01/17/2022 By Andrea

Article contributed by: Tristan Salomon, founder and CEO of Axom, and expert in Machine Learning, Big Data and AI. Any business needs to possess top-level technological advances not just to stand out from, but at least to keep up with the competition. This is especially true for pharmaceutical companies. The current pandemic situation has tested them […]

Pharma Leadership: Cultivating Talent in Uncertain Times

11/08/2021 By Andrea

Article contributed to PharmaLeaders and authored by: Beth Doladee, M.A., M.B.A., Managing Consultant and Neelima Paranjpey, Ph.D., Managing Consultant, The Vaya Group Executive Summary Today’s highly dynamic, fast-paced pharmaceutical industry requires knowledge preservation and leaders who understand these unique challenges. This means developing leadership from within, to preserve intellectual capital and ensure the right skills […]

Absci and Merck collaborate to develop new enzymes

01/17/2022

As part of the collaboration, the company will use its Deep Learning-Enabled Drug Creation and Bionic Protein non-standard amino acid technologies to create enzymes to meet Merck’s biomanufacturing The post Absci and Merck collaborate to develop new enzymes appeared first on Pharmaceutical Business … [Read More...]

US FDA approves Pfizer’s Cibinqo for atopic dermatitis treatment

01/17/2022

The latest move follows the receipt of European Commission (EC) approval for the drug in December last year. Cibinqo, the oral small molecule drug, selectively hinders Janus kinase The post US FDA approves Pfizer’s Cibinqo for atopic dermatitis treatment appeared first on Pharmaceutical Business … [Read More...]

Pfizer, Beam sign multi-target research collaboration for rare diseases

01/16/2022

The collaboration will see the base editing programmes to be evaluated leverage Beam’s in vivo delivery technologies. These technologies use messenger RNA (mRNA) and lipid nanoparticles (LNP) to The post Pfizer, Beam sign multi-target research collaboration for rare diseases appeared first on … [Read More...]

AbbVie seeks approval for upadacitinib to treat nr-axSpA

01/15/2022

A selective JAK inhibitor, Rinvoq is currently being analysed in various immune-mediated inflammatory diseases. Both the submissions are supported by the Phase III SELECT-AXIS 2 (Study 2) clinical The post AbbVie seeks approval for upadacitinib to treat nr-axSpA appeared first on Pharmaceutical … [Read More...]

Featured Article

How can pharmaceutical corporations successfully collaborate with tech startups?

Pharma Leadership: Cultivating Talent in Uncertain Times

White Papers

Whitepaper: Execute a 5-Step Framework for Data Compliance in Healthcare Marketing in the 2020s

The Future of Professional Medical Education

Industry News

Absci and Merck collaborate to develop new enzymes

US FDA approves Pfizer’s Cibinqo for atopic dermatitis treatment

Pfizer, Beam sign multi-target research collaboration for rare diseases

AbbVie seeks approval for upadacitinib to treat nr-axSpA